Thursday, September 29, 2022


Biotechnology News Magazine

Angiotensin Therapeutics Announces Publication of a Study Using a Soluble ACE2 Protein Designed for COVID-19

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Angiotensin Therapeutics Inc. (“Angiotensin” or the “Company”), a privately-held biopharmaceutical company focused on developing new therapies for COVID-19 and kidney disease announced the publication of a study entitled A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection by Hassler et al.

We are pleased to share proof of concept data that the virus that causes COVID-19, can be neutralized using a novel soluble angiotensin converting enzyme 2 (ACE2) protein that has an extended duration of action and strong binding to the receptor domain of the viral spike of SARS-CoV-2″ said Dr. Daniel Batlle, senior author of the paper, Professor of Medicine at Northwestern University Feinberg School of Medicine, and Founder of “Angiotensin”. “This journal article shows a remarkable improvement in survival of mice infected with the virus that received the protein as compared to those that did not” stated Dr. Jan Wysocki, MD, PhD, a co-author of the study.

“Angiotensin” is pursuing therapeutic applications to its best-in-class ACE2 enzyme proteins. “Even if the pandemic goes away, there will continue to be many situations, namely unvaccinated people and people infected with strains resistant other therapies; therefore, there is a need for additional approaches to combat different SARS-C0V-2 variants now and in the future. Our protein is effective in neutralizing all the variants of SARS-CoV2 tested in infected cells”, stated Dr. Batlle. The study published online in JASN were performed in a Biosafety level 3 facility where live virus can be used to infect mice with the virus that causes COVID-19 in humans. “This is evidence that this novel ACE2 protein should be efficacious for COVID-19 in humans” stated Luise Hassler, first author of the paper.

“We are excited to push forward with needed IND enabling studies leading to trials in patients with COVID-19” stated Mr. Cory Gutterman, interim CEO of Angiotensin Therapeutics.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine